drugset / Trial / NCT01526837
Bevacizumab (Avastin) Into the Tumor Resection Cavity in Subjects With Glioblastoma Multiforme at First Recurrence
NaSingle-groupOpen-labelTreatment
Summary
This is a phase 1b study for safety and tolerability of bevacizumab(Avastin)administered into the tumor resection cavity in subjects with Glioblastoma Multiforme (GBM) at first recurrence.
Timeline
- Start
- 2011-10
- Primary completion
- 2012-01
- Completion
- 2012-01
Outcome
Outcome not reported
Stopped: “Investigators decision”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 0.25 mg/ml | Topical |
| Subject | Bevacizumab | Monoclonal antibody | 25 mg/ml | Topical |